학술논문
Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response
Document Type
Article
Author
Otake-Kasamoto, Yuriko; Kayama, Hisako; Kishikawa, Toshihiro; Shinzaki, Shinichiro; Tashiro, Taku; Amano, Takahiro; Tani, Mizuki; Yoshihara, Takeo; Li, Bo; Tani, Haruka; Liu, Li; Hayashi, Akio; Okuzaki, Daisuke; Motooka, Daisuke; Nakamura, Shota; Okada, Yukinori; Iijima, Hideki; Takeda, Kiyoshi; Takehara, Tetsuo
Source
The Journal of Experimental Medicine; July 2022, Vol. 219 Issue: 7 pe20211291-e20211291, 1p
Subject
Language
ISSN
00221007; 15409538
Abstract
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.